Muromonab-CD3

Phase 2Small molecule

BBarbara Ann Karmanos Cancer Institute

Muromonab-CD3 is one of 151 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

MyocarditisActive, not recruiting

Blood DiseaseActive, not recruiting

OligodendrogliomaActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

MelanomaActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

MyocarditisPreclinical

Active, not recruiting

Blood DiseasePhase 2

Active, not recruiting

OligodendrogliomaPhase 2

Active, not recruiting

Bone Marrow TransplantationPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

13 2

Libtayo

Regeneron

Phase 3

6 3

Spartalizumab

Novartis

Phase 3

2 4

GSK 257049

GSK

Phase 3

1 5

Single Dose of

Boehringer Ingelheim

Phase 3

1 6

GSK2118436

GSK

Phase 3

1 7

Muromonab-CD3

BBarbara Ann Karmanos Cancer Institute

Phase 2

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myocarditis2 trials

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·N/A·NCT00027443·40 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Melanoma1 trial

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004022

Brain Tumors1 trial

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00002572·10 enrolled

Metastatic Cancer1 trial

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Unknown status·SSt. Vincent Medical Center - Los Angeles·Phase 1/2·NCT00002482

3 more indications

Kidney Cancer1 trial

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 2·NCT00002589·90 enrolled

Bone Marrow Transplantation1 trial

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005852

Oligodendroglioma1 trial

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004024·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Muromonab-CD3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Muromonab-CD3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Muromonab-CD3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Barbara Ann Karmanos Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBarbara Ann Karmanos Cancer Institute

Muromonab-CD3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myocarditis2 trials

Blood Disease1 trial

Melanoma1 trial

Brain Tumors1 trial

Metastatic Cancer1 trial

Kidney Cancer1 trial

Bone Marrow Transplantation1 trial

Oligodendroglioma1 trial

References

Drug Info

Quick Facts

Related News